SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): October 28, 2004.
BioTime, Inc.
(Exact name of registrant as specified in its charter)
California 1-12830 94-3127919
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
935 Pardee Street
Berkeley, California 94710
(Address of principal executive offices)
(510) 845-9535 (Registrant's
telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Statements made in this Report that are not historical facts may
constitute forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from those
discussed. Such risks and uncertainties include but are not limited to those
discussed in this report and in BioTime's Annual Report on Form 10-K filed with
the Securities and Exchange Commission. Words such as "expects," "may," "will,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar
expressions identify forward-looking statements.
Section 5- Corporate Governance and Management
Item 5.02. Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.
On October 28, 2004, the Board of Directors elected Valeta A. Gregg,
Ph.D., J.D. to the Board. Dr. Gregg is Vice President & Assistant General
Counsel, Patents for Regeneron Pharmaceuticals, Inc., a Tarrytown, New York
based company engaged in the development of pharmaceutical products for the
treatment of a number of serious medical conditions, including cancer, diseases
of the eye, rheumatoid arthritis and other inflammatory conditions, allergies,
asthma, and obesity. In her capacity at Regeneron Pharmaceuticals, Dr. Gregg is
responsible for company-wide patent-related activities. Prior to joining
Regeneron Pharmaceuticals, Dr. Gregg was Senior Patent Attorney for Novo Nordisk
of North America.
Dr. Gregg received her J.D. from the University of Colorado School of Law
in 1992. She completed her Ph.D. in Biochemistry at the University of Alberta,
Edmonton Alberta Canada in 1982 and was a Post-Doctorial Fellow at Columbia
University from 1983-1986. Dr. Gregg conducted her undergraduate and graduate
studies in Human Nutrition at the University of California at Davis (M.S. 1977;
B.S., 1975)
Although the Board has not yet determined whether Dr. Gregg will be
appointed to any of its committees, as an independent director, within the
meaning of American Stock Exchange Rule 121A, she is eligible to serve on the
Board's Audit, Compensation and Nominating Committees.
Dr. Gregg is replacing Jeffrey B. Nickel, Ph.D. on the Board. Dr. Nickel
has stepped down in order to focus on his duties as Vice President of Business
Development and Marketing. Dr. Nickel was appointed to that position effective
June 1, 2004.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOTIME, INC.
Date: November 2, 2004 By /s/ Steven Seinberg
-----------------------
Steven Seinberg,
Chief Financial Officer
3
Exhibit
Numbers Description
-------- -----------
99.1 Press Release dated November 2, 2004